Compare AQN & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AQN | FOLD |
|---|---|---|
| Founded | 1988 | 2002 |
| Country | Canada | United States |
| Employees | 3786 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.5B |
| IPO Year | N/A | 2006 |
| Metric | AQN | FOLD |
|---|---|---|
| Price | $6.16 | $14.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $6.57 | ★ $27.25 |
| AVG Volume (30 Days) | ★ 4.4M | 3.0M |
| Earning Date | 03-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.19% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.34 | $20.50 |
| Revenue Next Year | $4.77 | $18.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.45 | $5.66 |
| 52 Week High | $7.11 | $14.43 |
| Indicator | AQN | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 35.97 | 69.49 |
| Support Level | $5.99 | $14.21 |
| Resistance Level | $6.13 | N/A |
| Average True Range (ATR) | 0.15 | 0.02 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 3.81 | 81.25 |
Algonquin Power & Utilities Corp is a Canada-based diversified international generation, transmission, and distribution company. The company's operations are organized across two business units: the Regulated Services Group, which owns and operates a portfolio of regulated electric, water distribution, and wastewater collection, and natural gas utility systems and transmission operations in the United States, Canada, Bermuda, and Chile; and the Hydro Group, which consists of hydroelectric-generating facilities located in Canada. It generates the majority of its revenue from the Regulated Services Group segment.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.